Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Australia for the Treatment of Individuals with Multiple System Atrophy October 13, 2022October 13, 2022
European Commission Approves PBT2 Orphan Designation for Huntington’s Disease June 1, 2015August 16, 2022